HER2/EGFR in Cancer Research
Most cited papers
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience · 1987 · 11,862 citations
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine · 2001 · 11,674 citations
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine · 2004 · 11,565 citations
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience · 2004 · 9,452 citations
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience · 1989 · 6,856 citations
- Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine · 2017 · 5,640 citations
- Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast CancerNew England Journal of Medicine · 2005 · 5,438 citations
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine · 2005 · 5,157 citations
- Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal CancerNew England Journal of Medicine · 2004 · 5,069 citations
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience · 2007 · 4,559 citations
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerJournal of Clinical Oncology · 2006 · 4,428 citations
- Trastuzumab-Induced Hepatotoxicity: A Case ReportBreast Care · 2013 · 4,416 citations
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences · 2004 · 4,371 citations
Metadata from OpenAlex (CC0).